Open Orphan plc changed its name to hVIVO plc on 26 October 2022, learn more here.

Articles & Research
from hVIVO

Scientific Paper

Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults

Infectious Diseases Blog – ‘The Pathogenda’ Part 1

Scientific Paper

EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge

Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge

hLab – Virology Laboratory Services

The annual challenge of the global health community is progressing innovative products (vaccines, antiviral drugs, immunomodulators) for the control of infections of significant disease burden in a timely manner at...

Human Challenge Trials as a tool in raising funding

Introduction challenge trials In human challenge studies (HCT) or Controlled Human Infection Models (CHIM), healthy volunteers are administered a pathogenic or virulent strain of a challenge agent, which can be...

SARS-CoV-2 Human Challenge Studies — Establishing the Model during an Evolving Pandemic

Don't be afraid of the FDA

How Human Challenge Trials Can Accelerate Vaccine Development

Rolling Reviews – a useful tool to speed up the regulatory review process

Rolling reviews have been in the media spotlight because of a global need to approve COVID-19 treatments and vaccines quickly. This article provides an overview of how rolling reviews work...